CEREBROLYSIN 215.2MG/ML I.M./I.V. 10 AMPS (1ML)

Cerebrolysin a peptide preparation produced from purified pig brain proteins may have positive effects on cognitive function in older patients with vascular dementia (VaD) according to a new meta-analysis. Cerebrolysin is a mixture of 80% low-molecular-weight peptides and 20% free amino acids. Various studies have shown that the agent s multiple effects include promotion of neuroprotection neuroplasticity and neurogenesis. It is approved in many countries for treatment of Alzheimer s disease (AD) stroke and/or traumatic brain injury although not in the United States. A Cochrane review of Cerebrolysin for stroke published in 2010 concluded there was not enough evidence to evaluate its use in stroke and a review of its use in AD is underway the authors note.